About Us

Precision diagnostics for metabolic disease, built for real-world clinical use

Advancing global health through non-invasive metabolic detection

MASLD-first design

Quantitative outputs

No grey zones

Built for scalability

Screening, staging, and monitoring metabolic disease from blood A single blood draw. Comprehensive metabolic profile. Scalable screening for entire populations. Establishing the diagnostic foundation for the future of metabolic care.

Fibronostics leadership

Albert Hummel

Executive Chairman

Brock Smith

Chief Executive Officer

 

John Lee

Chief Technology Officer, Director International

Dr Mona Munteanu

Chief Scientific Officer, MD, PHD

Sven Henrichwark

Director Strategic Initiatives

 

David Cashio

Director Business Operations

 

Paul Caudill

Director, Revenue Cycle and Payer Relations

Hear it directly from the experts

Dedicated to providing expert healthcare advanced technology, experienced professionals, and personalized treatments to ensure your well-being and a healthier future.

“For over a decade, I have used LIVERFASt™ as my primary non-invasive test for assessing patients with MASLD. What initially impressed me was its ability to assess steatosis, activity and fibrosis from a single blood test. I have also observed encouraging agreement between LIVERFASt and Magnetic Resonance Elastography (MRE), which led to our collaborative research presented at DDW 2026. LIVERFASt remains a valuable tool in my clinical practice for assessing liver health, identifying patients at risk and supporting ongoing monitoring.”

Garth O George MD FACG

Advanced Gastroenterology & Surgery Associates Leesburg/Lady Lake, FL

“LIVERFASt™ is a very reliable test that facilitates my care of MASH patients”

Picture of Dr. Victor Ankoma-Sey

Dr. Victor Ankoma-Sey

Director of Liver Transplant Program at Houston Methodist Transplant Center and Director of Liver Associates of Texas Houston, TX

“In my opinion the science and subsequent validation of the LIVERFASt™ test, fulfills a strong and unmet need for accurate diagnosis and monitoring of MASH .”

Picture of Dr. Parvez Mantry

Dr. Parvez Mantry

Executive Medical Director Scientific Affairs, Innovation and New Technology, Methodist Health System, Plano,
TX

“MASH accounts for about 20-25% of all MASLD patients and can be challenging to diagnose… LIVERFASt™, uniquely gives us an opportunity to identify these patients and direct them to appropriate care that may help prevent progression of their disease.”

Picture of Dr. Naim Al Khouri

Dr. Naim Al Khouri

Chief Medical Officer (CMO), Summit Clinical Research. Director of the Steatotic Liver Program. Clinical Research Institute of Ohio (CRIOH)

Interested in partnering with us?

Contact our sales representative to inquire more about LIVERFASt™ and how it can help you and your patients improve their liver health.